摘要 |
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of BMS-790052 (daclatasvir) and BMS-650032 (asunaprevir) and an inhibitor of cytochrome P450 (e.g., ritonavir). |
申请人 |
ABBVIE INC. |
发明人 |
BERNSTEIN, BARRY M.;MENON, RAJEEV M.;KHATRI, AMIT;MENSING, SVEN;DUTTA, SANDEEP;COHEN, DANIEL E.;PODSADECKI, THOMAS J.;BRUN, SCOTT C.;AWNI, WALID M.;DUMAS, EMILY O.;KLEIN, CHERI E. |